Health

Germany's Merck seeks partners for cancer and immune system drugs

FRANKFURT (Reuters) - Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.

Top News

Novartis confirms 2018 targets as Alcon recovery gains steam

ZURICH (Reuters) - Swiss drugmaker Novartis confirmed 2018 growth targets on Thursday as new Chief Executive Officer Vas Narasimhan said he was encouraged by first-quarter performance by his cancer drugs portfolio and a resurgent Alcon eye care unit.

Health

AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

(Reuters) - U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

Health

GSK grabs Roche cancer expert to lead pharma pipeline deals

LONDON (Reuters) - GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development.

Health

More activity, healthier diet tied to extended survival after colon cancer

(Reuters Health) - Colon cancer survivors with healthier lifestyles may live longer, a recent U.S. study suggests.

Business

J&J quarterly profit beats on demand for cancer drugs

(Reuters) - Johnson & Johnson reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by growing demand for its cancer drugs.

Health

U.S. public may lack understanding of cancer screening

(Reuters Health) - Most people have inaccurate beliefs about what cancer screening tests can do and what they cannot, suggests a recent study from the U.S. National Cancer Institute.

Health

Coffee industry worried U.S. ruling on cancer warning may widen

MEXICO CITY (Reuters) - The head of the International Coffee Organization criticized a U.S. judge's decision requiring cancer warnings on coffee sold in California by Starbucks and other retailers, expressing concern that the push for cancer labels may sp

Health

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

(Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement t

Business

J&J Baby Powder litigation takes new focus with asbestos claims

NEW YORK (Reuters) - A $117 million verdict against Johnson & Johnson and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J's Baby Powder could open a new front for thousands of cases claiming the widely

Health

As cancer drug prices climb, value not keeping pace

(Reuters Health) - The cost of new anti-cancer drugs increased more than five-fold from 2006 to 2015, but a new analysis suggests that cancer patients and insurers may be getting less for their money.

Health

China to remove tariffs on imported cancer drugs from May 1: state media

BEIJING (Reuters) - China will remove import tariffs on cancer drugs from May 1, state media reported on Thursday, citing a meeting of the State Council, or cabinet, chaired by Premier Li Keqiang.

Health

Few Americans aware of cancer drug shortages

(Reuters Health) - Most Americans aren't aware of cancer drug shortages that might lead some patients to receive less effective or more toxic treatments, a U.S. study suggests.

Health

Merck's Keytruda meets main goal in lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial testing its blockbuster cancer drug, Keytruda, met the main goal of helping previously untreated lung cancer patients live longer.

Health

Incyte, Merck melanoma combo therapy fails study, shares slide

(Reuters) - Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co's Keytruda failed to meet the main goal in a late-stage study.

United States

U.S. Medicare sets outpatient rate for Yescarta reimbursement

(Reuters) - Medicare, the U.S. government healthcare program for the elderly and disabled, will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000,

United States

J&J, Imerys must pay $37 million in case over talc cancer risks: jury

(Reuters) - Johnson & Johnson and Imerys SA must pay at least $37 million in a lawsuit claiming a man developed cancer due to his exposure to asbestos in talc-based products including Johnson's Baby Powder, a New Jersey state court jury said on Thursday

Health

Lilly's Cyramza succeeds in late-stage liver cancer trial

(Reuters) - Eli Lilly and Co on Wednesday said its drug Cyramza met the main goal of helping patients live longer in a late-stage trial, which tested it as a potential treatment for the most common type of liver cancer.

Other news portals: S4news.in, S4news.de, S4news.ru
Other portals: Property for sale in UK, S4jobs.com, Best jobs in United Kingdom, Beste jobs in Deutschland.